A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)

被引：10
|
作者：
Goto, Y. [1 ]
Okada, M. [2 ]
Kijima, T. [3 ]
Aoe, K. [4 ]
Kato, T. [5 ]
Fujimoto, N. [6 ]
Nakagawa, K. [7 ]
Takeda, Y. [8 ]
Hida, T. [9 ]
Kanai, K. [10 ]
Imamura, F. [11 ]
Oizumi, S. [12 ]
Takahashi, T. [13 ]
Takenoyama, M. [14 ]
Tanaka, H. [15 ]
Ohe, Y. [16 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Hiroshima Univ, Hiroshima, Japan
[3] Hyogo Coll Med, Nishinomiya, Hyogo, Japan
[4] Natl Hosp Org Yamaguchi Ube Med Ctr, Ube, Yamaguchi, Japan
[5] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[6] Okayama Rosai Hosp, Asbestos Study Ctr, Okayama, Japan
[7] Kinki Univ, Fac Med, Med Oncol, Osaka, Japan
[8] Natl Ctr Global Hlth & Med, Resp Med, Tokyo, Japan
[9] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[10] Wakayama Med Univ, Wakayama, Japan
[11] Osaka Int Canc Inst, Dept Gen Thorac Surg, Osaka, Japan
[12] Natl Hosp Org Hokkaido Canc Ctr, Dept Resp Med, Sapppro, Japan
[13] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[14] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka, Japan
[15] Niigata Canc Ctr Hosp, Internal Med, Niigata, Japan
[16] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
malignant pleural mesothelioma; Nivolumab; PD-1;
D O I：
10.1016/j.jtho.2017.09.634
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 19.01
引用
收藏
页码：S1883 / S1883
页数：1
相关论文
共 50 条
  • [1] A phase II study of nivolumab: a multicenter, open-label, single arm study in malignant pleural mesothelioma (MERIT)
    Aoe, Keisuke
    Okada, Morihito
    Kijima, Takashi
    Kato, Terufumi
    Fujimoto, Nobukazu
    Nakagawa, Kazuhiko
    Takeda, Yuichiro
    Hida, Toyoaki
    Kanai, Kuninobu
    Imamura, Fumio
    Oizumi, Satoshi
    Takahashi, Toshiaki
    Takenoyama, Mitsuhiro
    Tanaka, Hiroshi
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)
    Okada, Morihito
    Kijima, Takashi
    Aoe, Keisuke
    Kato, Terufumi
    Fujimoto, Nobukazu
    Nakagawa, Kazuhiko
    Takeda, Yuichiro
    Hida, Toyoaki
    Kanai, Kuninobu
    Imamura, Fumio
    Oizumi, Satoshi
    Takahashi, Toshiaki
    Takenoyama, Mitsuhiro
    Tanaka, Hiroshi
    Hirano, Jun
    Namba, Yoshinobu
    Ohe, Yuichiro
    CLINICAL CANCER RESEARCH, 2019, 25 (18) : 5485 - 5492
  • [3] Clinical efficacy and safety of nivolumab in malignant non-pleural mesothelioma: A multicenter, open-label, single-arm, Japanese phase II trial (VIOLA) protocol
    Kuribayashi, Kozo
    Igeta, Masataka
    Daimon, Takashi
    Maede, Ibu
    Suna, Shinichiro
    Okamoto, Rika
    Kijima, Takashi
    ONCOLOGY, 2023, 101 (04) : 257 - 261
  • [4] Ipilimumab and Nivolumab in the Treatment of Recurrent Malignant Pleural Mesothelioma: A Phase II Study
    Disselhorst, M.
    Harms, E.
    Van Tinteren, H.
    Quispel-Janssen, J.
    Monkhorst, K.
    Burgers, S.
    Baas, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1746 - S1746
  • [5] Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial
    Bayman, Neil
    Appel, Wiebke
    Ashcroft, Linda
    Baldwin, David R.
    Bates, Andrew
    Darlison, Liz
    Edwards, John G.
    Ezhil, Veni
    Gilligan, David
    Hatton, Matthew
    Jegannathen, Apurna
    Mansy, Talal
    Peake, Michael D.
    Pemberton, Laura
    Rintoul, Robert C.
    Snee, Michael
    Ryder, W. David
    Taylor, Paul
    Faivre-Finn, Corinne
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1200 - +
  • [6] An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
    Agulnik, Mark
    Schulte, Brian
    Robinson, Steven
    Hirbe, Angela C.
    Kozak, Kevin
    Chawla, Sant P.
    Attia, Steven
    Rademaker, Alfred
    Zhang, Hui
    Abbinanti, Susan
    Cehic, Rasima
    Monga, Varun
    Milhem, Mohammed
    Okuno, Scott
    Van Tine, Brian A.
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 201 - 208
  • [7] Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study
    Cortinovis, Diego
    Grosso, Federica
    Carlucci, Luciano
    Zucali, Paolo Andrea
    Pasello, Giulia
    Tiseo, Marcello
    Sperandi, Francesca
    Hollander, Lital
    Galli, Francesca
    Torri, Valter
    Rulli, Eliana
    Canova, Stefania
    Maconi, Antonio
    Bidoli, Paolo
    Ceresoli, Giovanni Luca
    D'Incalci, Maurizio
    CLINICAL LUNG CANCER, 2021, 22 (04) : 361 - +
  • [8] Three-year follow-up results of the MERIT trial: A Japanese phase II study of nivolumab in malignant pleural mesothelioma
    Hayashi, H.
    Okada, M.
    Kijima, T.
    Aoe, K.
    Kato, T.
    Fujimoto, N.
    Nakagawa, K.
    Takeda, Y.
    Hida, T.
    Kanai, K.
    Hirano, J.
    Namba, Y.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1076 - S1076
  • [9] An Open-label Phase I Pilot Study of Continuous Intrapleural Infusion of Escalated Doses of Methotrexate in Malignant Pleural Mesothelioma
    Ellithy, Mahmoud Mahmoud Abbass
    El Baghdady, Noha Salah El Din M.
    El Wakeel, Lamia Mohamed
    Abdeltawab, Karim Ahmed
    Badary, Osama Ahmed
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (05): : 514 - 518
  • [10] Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
    Tanizaki, J.
    Yonemori, K.
    Akiyoshi, K.
    Minami, H.
    Ueda, H.
    Takiguchi, Y.
    Miura, Y.
    Segawa, Y.
    Takahashi, S.
    Iwamoto, Y.
    Kidera, Y.
    Fukuoka, K.
    Ito, A.
    Chiba, Y.
    Sakai, K.
    Nishio, K.
    Nakagawa, K.
    Hayashi, H.
    ANNALS OF ONCOLOGY, 2022, 33 (02) : 216 - 226
12345